{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=99",
    "query": {
      "condition": "Multi Center",
      "page": 99
    },
    "page_size": 10
  },
  "pagination": {
    "page": 99,
    "page_size": 10,
    "total_count": 6602,
    "total_pages": 661,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=100&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=98&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-11T00:09:05.627Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00211887",
      "title": "Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Interferon beta 1-a",
          "type": "DRUG"
        },
        {
          "name": "glatiramer acetate",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Fred Lublin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 1008,
      "start_date": "2005-01",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-03",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 67,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00211887"
    },
    {
      "nct_id": "NCT00888914",
      "title": "Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lateral Canthal Lines",
        "Crow's Feet",
        "Facial Wrinkles"
      ],
      "interventions": [
        {
          "name": "RT001",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Comparator",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Revance Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "30 Years to 55 Years"
      },
      "enrollment_count": 60,
      "start_date": "2008-11",
      "completion_date": "2009-02",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • New York, New York • White Plains, New York",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888914"
    },
    {
      "nct_id": "NCT04485104",
      "title": "Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seizure in Participants With Tuberous Sclerosis Complex",
        "Seizure in Participants With Dravet Syndrome",
        "Seizure in Participants With Lennox-Gastaut Syndrome"
      ],
      "interventions": [
        {
          "name": "GWP42003-P",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "1 Month to 23 Months"
      },
      "enrollment_count": 3,
      "start_date": "2021-05-19",
      "completion_date": "2025-01-28",
      "has_results": true,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04485104"
    },
    {
      "nct_id": "NCT00130000",
      "title": "Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Paroxysmal Hemoglobinuria, Nocturnal"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2005-08-09",
      "completion_date": "2007-06-25",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00130000"
    },
    {
      "nct_id": "NCT06147336",
      "title": "A Multi-center, National, Open-label, Prospective Study to Evaluate the Performance of the V-Lap™ System",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "V-LAP™ SYSTEM",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vectorious Medical Technologies Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "88 Years",
        "sex": "ALL",
        "summary": "22 Years to 88 Years"
      },
      "enrollment_count": 10,
      "start_date": "2024-06-11",
      "completion_date": "2028-04",
      "has_results": false,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06147336"
    },
    {
      "nct_id": "NCT01565707",
      "title": "A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urinary Bladder, Overactive"
      ],
      "interventions": [
        {
          "name": "Solifenacin Succinate Suspension",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Urotherapy",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "Astellas Pharma Europe B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 189,
      "start_date": "2012-06-07",
      "completion_date": "2014-01-02",
      "has_results": true,
      "last_update_posted_date": "2024-10-31",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 2,
      "location_summary": "Shreveport, Louisiana • Albany, New York",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Albany",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01565707"
    },
    {
      "nct_id": "NCT01602393",
      "title": "Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CHF 5074 1x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 2x",
          "type": "DRUG"
        },
        {
          "name": "CHF 5074 3x",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 51,
      "start_date": "2012-05",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 4,
      "location_summary": "Eatontown, New Jersey • Monroe Twp, New Jersey • Toms River, New Jersey + 1 more",
      "locations": [
        {
          "city": "Eatontown",
          "state": "New Jersey"
        },
        {
          "city": "Monroe Twp",
          "state": "New Jersey"
        },
        {
          "city": "Toms River",
          "state": "New Jersey"
        },
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602393"
    },
    {
      "nct_id": "NCT03290300",
      "title": "Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Nasal Obstruction"
      ],
      "interventions": [
        {
          "name": "Vivaer Stylus",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Aerin Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2017-10-30",
      "completion_date": "2022-07-09",
      "has_results": true,
      "last_update_posted_date": "2024-02-15",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 8,
      "location_summary": "Fresno, California • Colorado Springs, Colorado • Oradell, New Jersey + 5 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Oradell",
          "state": "New Jersey"
        },
        {
          "city": "Bayside",
          "state": "New York"
        },
        {
          "city": "Middletown",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03290300"
    },
    {
      "nct_id": "NCT01278134",
      "title": "A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus placebo",
          "type": "DRUG"
        },
        {
          "name": "RO5024048",
          "type": "DRUG"
        },
        {
          "name": "danoprevir",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a [Pegasys]",
          "type": "DRUG"
        },
        {
          "name": "ribavirin [Copegus]",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 170,
      "start_date": "2011-02",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 18,
      "location_summary": "La Jolla, California • Sacramento, California • Orlando, Florida + 14 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01278134"
    },
    {
      "nct_id": "NCT00053599",
      "title": "Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2002-12",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2009-07-28",
      "last_synced_at": "2026-11-11T00:09:05.627Z",
      "location_count": 44,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00053599"
    }
  ]
}